Remagine Labs and Praxis Precision Medicines Announce Strategic Collaboration

Today we announced a research collaboration and license agreement with Praxis Precision Medicines (Nasdaq: PRAX) to develop an iontophoretic transdermal patch for ulixacaltamide, Praxis's lead therapy in development for essential tremor. Praxis has also made an equity investment in Remagine Labs.

We're proud to partner with Praxis on this next step for our platform, and grateful for the continued support of the University of Melbourne, Monash University, the Genesis Pre-Seed Fund, Innovation Victoria, and the Australian Government's Cooperative Research Centres Program.

Read the full press release here.